Focused on a global “dual sourcing” strategy, China-headquartered contract research, development and manufacturing organization (CRDMO) WuXi Biologics is accelerating its production capacity expansion globally through continued investments and strategic asset acquisitions, according to unaudited interim financial results for the first half of 2026.

WuXi Biologics reported revenue of RMB 11.8 billion in the first half of 2026, growing 18.4% year-over-year. Complex biologics modalities such as antibody-drug conjugates (ADCs) and bi-/multi-specific antibodies continued to drive business growth in the first half of 2026, contributing more than 50% of revenue — an increase of approximately 30% year-over-year.

As of the end of June, the CRDMO reported it is supporting more than 1,000 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing — with complex modalities representing more than half of its project portfolio.

Chris Chen, CEO of WuXi Biologics, said in a statement that the pipeline continues to provide strong visibility into future manufacturing revenue growth, noting complex biologics accounted for more than 70% of new projects in the first half of 2026.

“We will continue to expand capacity and optimize our business portfolio in a demand-driven and disciplined manner, while investing in differentiated technologies and our global network to support sustained growth and long-term value creation for clients and shareholders,” Chen said.

WuXi Biologics is advancing its digital manufacturing capabilities with PatroLab, a digital twin platform combining real-time process monitoring with Raman-based Process Analytical Technology (PAT) and predictive in silico modeling to enhance process performance, shorten development timelines, and ensure consistent, high-quality biologics production.

Process Performance Qualification (PPQ) is a critical step for WuXi Biologics in the development of biologics to assess the ability of a manufacturing process to consistently produce high-quality products. The company claims it has maintained a 100% PPQ campaign success rate to date, with 34 PPQs scheduled in 2026 and 30 PPQs in 2027.

Backed by a team of more than 1,000 quality experts, WuXi Biologics has completed 49 regulatory inspections including 23 by the FDA and European Medicines Agency, with no critical findings or data integrity observations. As of the end of June 2026, the company said it has obtained 166 facility license approvals across its global network and operated 15 GMP-certified manufacturing facilities. 

Last month, WuXi Biologics received FDA Pre-License Inspection approval for its MFG8 drug substance manufacturing facility in Hebei, China, clearing the site to support commercial manufacturing of an investigational autoimmune therapy.

In June, the CRDMO received GMP certification from Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA) for three manufacturing facilities in Wuxi, China, enabling end-to-end commercial production of an anti-PD-L1 monoclonal antibody for the Brazilian market. That same month, WuXi Biologics completed its first GMP production campaign at MFG17, the company’s Shanghai Fengxian site in China.

Also in June, the CRDMO completed the structural topping-out of a drug product facility at its Singapore hub in Tuas Biomedical Park. The facility is expected to provide approximately 100 million units of annual pre-filled syringe and vial capacity when operations begin in 2027. The hub will add 120,000 liters of manufacturing capacity to the company’s global network.

Construction of MFG11 in Worcester, Massachusetts — with 36,000L (6 x 6,000L) of commercial manufacturing capacity — is progressing as planned, according to an update this week from WuXi Biologics. In Cranbury, New Jersey, the company said MFG18 is being upgraded from a clinical manufacturing facility to have commercial manufacturing capabilities with more than 13,000L of total capacity, and initiated its first PPQ campaign in the first half of 2026.

Growing its global workforce

Currently, WuXi Biologics has more than 14,000 employees in China, Germany, Ireland, Singapore, and the U.S. — including over 5,100 scientists — with plans to further expand its workforce in the second half of 2026.

Chen explained in an interview earlier this year with Pharma Manufacturing that from contract signing, a senior cross-functional chemical, manufacturing, and controls (CMC) lead and project manager are assigned to each client project.

“A dedicated CMC team is formed within two weeks, and the project is launched within four weeks,” Chen said. “The commercial manufacturing team also includes over 800 experts spanning hundreds of disciplines. Subject matter experts with deep technical expertise make up over 60% of the team, while function leads focus on collaboration. These two roles complement each other, driving quality and efficiency throughout manufacturing.” 

At a time when workforce shortages are the global biomanufacturing sector’s most pressing constraint, WuXi Biologics contends it has a key talent retention rate of 98.7%.